Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial-Reference-Cited by-同舟云学术

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

Published:2009-01 Issue:9660 Volume:373 Page:301-308
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Widmark Anders,Klepp Olbjørn,Solberg Arne,Damber Jan-Erik,Angelsen Anders,Fransson Per,Lund Jo-Åsmund,Tasdemir Ilker,Hoyer Morten,Wiklund Fredrik,Fosså Sophie D

Publisher

Elsevier BV

Subject

General Medicine

Reference34 articles.

1. Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials;Boustead;Br J Urol Int,2007

2. Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone;Granfors;J Urol,2006

3. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer;Horwitz;J Clin Oncol,2008

4. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413;Roach;J Clin Oncol,2003

5. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial;D'Amico;JAMA,2008

Cited by 748 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Delayed definitive management of localized prostate cancer: what do we know?;Prostate Cancer and Prostatic Diseases;2024-08-11

2. Effect of Radical Prostatectomy on Survival for Men with High-risk Nonmetastatic Prostate Cancer Features Selected According to STAMPEDE Criteria: An EMPaCT Study;European Urology Oncology;2024-07

3. Overview of Radiation Therapy in the Management of Localized and Metastatic Prostate Cancer;Current Urology Reports;2024-06-11

4. Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate–High-Risk Prostate Cancer: Insights from a Phase I/II Study;Cancers;2024-05-31

5. Differences in real‐world outcomes by risk classification for localized prostate cancer patients after radiation therapy;The Prostate;2024-04-29